Peter1962的个人主页 - 老虎社区

Peter1962

Peter1962

暂无个人介绍

IP属地：未知

21关注

3粉丝

0主题

0勋章

2021-12-20

It started with a cult following. The innovation has simmer abit compared to previous Job’s years but I am hopeful that some new breakthrough willcontinue in the communication space. They did well in the “wearable” when they make I watch a potential medical grade device for cardio.Everyone is into AR but actually making it immersive and ambient so that adoption is intuitive would require the likes of Job or Ian or Elon to drive the “work of Perfection “ in innovation and design.With the bourse it has, I agree that it’s a good haven at a right price and a good chance for upsideif they put more weight into their innovation.

Apple Stock: The Strongest Shield Against Rate Hikes

2021-12-13

$Apple(AAPL)$Wow beyond my expectation ! GoApple go!

2021-12-09

Apple is premium stock. So when Low get in to keep for the long run. Strong brand and innovativewith sight on EV market expanding their VP to embrace a wider lifestyle market.

2021-12-08

$SINGAPORE AIRLINES LTD(C6L.SI)$Always good to buy some and keep.This is a premium airline stock that has strong government support in a very structured and organised country. When things open up this will fly!

2021-11-05

This means long term growth!!!!

Pfizer Develops Covid Pill That Cuts Hospitalizations and Deaths by 89%

2021-11-04

Trying market now

2021-11-04

$Pfizer(PFE)$Betting on Pfizer to grow!

2021-11-04

$Pfizer(PFE)$Is good place to go in now . Covid will be around for another 5 years… no matter what we do.

2021-09-07

Apple will be good for next 6 months

抱歉，原内容已删除

2021-08-30

Still good to go… target maybe can be 45

2021-08-27

Time to go in at its lowest

2021-08-27

Interest pop up!

抱歉，原内容已删除

2021-08-06

AMD consolidating stock price to earnings results. If chip shortage prolong … prices will start to rise

2021-07-29

$Intel(INTC)$Good to go in… chip shortage will rebound

2021-07-27

What is paper accou t for ?

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4089970209759400","uuid":"4089970209759400","gmtCreate":1626868582248,"gmtModify":1627522464325,"name":"Peter1962","pinyin":"peter1962","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":21,"tweetSize":15,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.07","exceedPercentage":"93.13%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.88%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":693318282,"gmtCreate":1639970145691,"gmtModify":1639971034307,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"It started with a cult following. The innovation has simmer abit compared to previous Job’s&nbsp;years but I am hopeful that some new breakthrough willcontinue in the communication space.&nbsp;They did well in the “wearable” when they make I watch a potential medical grade device for cardio.Everyone is into AR but actually making it immersive and ambient so that adoption is intuitive would require the likes of Job or Ian or Elon to drive the “work of Perfection “ in innovation and design.With the bourse it has, I agree that it’s a good haven at a right price and a good chance for upsideif they put more weight into their innovation.","listText":"It started with a cult following. The innovation has simmer abit compared to previous Job’s&nbsp;years but I am hopeful that some new breakthrough willcontinue in the communication space.&nbsp;They did well in the “wearable” when they make I watch a potential medical grade device for cardio.Everyone is into AR but actually making it immersive and ambient so that adoption is intuitive would require the likes of Job or Ian or Elon to drive the “work of Perfection “ in innovation and design.With the bourse it has, I agree that it’s a good haven at a right price and a good chance for upsideif they put more weight into their innovation.","text":"It started with a cult following. The innovation has simmer abit compared to previous Job’s years but I am hopeful that some new breakthrough willcontinue in the communication space. They did well in the “wearable” when they make I watch a potential medical grade device for cardio.Everyone is into AR but actually making it immersive and ambient so that adoption is intuitive would require the likes of Job or Ian or Elon to drive the “work of Perfection “ in innovation and design.With the bourse it has, I agree that it’s a good haven at a right price and a good chance for upsideif they put more weight into their innovation.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693318282","repostId":"1183475424","repostType":4,"repost":{"id":"1183475424","kind":"news","pubTimestamp":1639967829,"share":"https://www.laohu8.com/m/news/1183475424?lang=&edition=full","pubTime":"2021-12-20 10:37","market":"us","language":"en","title":"Apple Stock: The Strongest Shield Against Rate Hikes","url":"https://stock-news.laohu8.com/highlight/detail?id=1183475424","media":"Seeking Alpha","summary":"Summary\n\nWith inflation running its hottest course in 40 years, the Federal Reserve has decided to a","content":"<p><b>Summary</b></p>\n<ul>\n <li>With inflation running its hottest course in 40 years, the Federal Reserve has decided to accelerate the stimulus tapering schedule and prepare for raising interest rates as early as March.</li>\n <li>While rate hikes have historically deterred investors from growth stocks due to concerns over eroding valuation prospects, the Apple stock has remained largely resilient.</li>\n <li>Apple is expected to realize additional upsides ahead, sustained by robust demand for its existing offerings and new opportunities arising from nascent technologies like AR/VR and autonomous vehicles.</li>\n <li>Its strong net cash position also provides sufficient dry powder to fund additional growth in coming years without incurring additional costs of capital amidst rising interest rates.</li>\n <li>As such, Apple's bullish thesis remains intact as it approaches a $3 trillion valuation, despite broader market valuation risks ahead.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fdf73ac36a98ce54b343c7e6b613f4d9\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"><span>guvendemir/iStock Unreleased via Getty Images</span></p>\n<p>As one of the world’s best performing stocks, Apple(NASDAQ:AAPL)&nbsp;has gained close to 40% this year. The stock, which last peaked at $182.13 not too long ago, is currently less than 7% from being the first U.S. publicly listed company to reach a $3 trillion market value and single-handedly accounts for about 15% of the tech-heavy Nasdaq 100’s performance. Apple’s market value has grown by&nbsp;more than 220x&nbsp;since the late 1990s, buoyed by the company’s continuous ability to capture robust demand for its innovative portfolio of products and services.</p>\n<p>And Apple’s strong fundamentals are expected to help the stock defy adverse impacts from the imminent rate hikes beginning next year. With inflation running at its hottest in almost four decades, the Federal Reserve decided Wednesday that it will increase the pace at which it is dialing back on the $120 billion monthly bond repurchasing program from $15 billion per month, which began in November, to&nbsp;$30 billion per month. This would effectively conclude the stimulus program, put in place at the onset of the pandemic, coming March, rather than in&nbsp;July as initially planned. Rate hikes are expected to begin soon after to counter rising price pressures, with Federal Reserve Chair Jerome Powell affirming that the process will only begin after tapering ends and at a gradual pace. The latest dot plot indicates potential for the Federal Fund Rate to lift-off from near-zero beginning early 2022 with three quarter-point increases, plus another three in 2023 and two more in 2024. If materialized, the process would up the funds rate to 2.1% by 2024.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2ef3ca2d04c1b55a465e12bfae79890e\" tg-width=\"640\" tg-height=\"315\" width=\"100%\" height=\"auto\"><span>Source: Bloomberg</span></p>\n<p>While rate hikes typically cause investors to turn risk averse due to concerns over&nbsp;faster erosion of value on future gains&nbsp;and stalled business growth due to rising costs of capital, especially for high-growth stocks, Apple gained close to 3% upon release of the Fed’s update on policy tightening. The stock closed at $179.30 on December 15th, nearing its peak of $182 on Monday. Apple’s rally, along with similar uptrends observed across other mega-cap tech stocks, accordingly drove intra-day gains of 2.4% for the Nasdaq 100 following the Federal Reserve’s update, indicating investors’ preference to park their money in companies with robust growth prospects to counter risks from the impending rate increases.</p>\n<p>With the coming holiday season a boon for Apple’s December-quarter sales, the stock’s valuation is expected to enter in the $3 trillion territory sooner than expected. Continued robust demand observed across Apple’s entire product line, generous share buy-backs, and additional revenue contributions expected within the foreseeable future resulting from new, cutting-edge products will also be key catalysts to support the company’s persistently strong fundamentals and keep the stock’s valuation above $3 trillion despite the impending rate hikes. Considering recent developments to the broader market and Apple’s growth prospects, we are raising our 12-month price target for the stock to $209.43.</p>\n<p><b>FY 2021 Overview and Recap of Fundamental Prospects</b></p>\n<p>Fiscal 2021 was a big year for Apple. The company’s revenues for the year grew 33% from fiscal 2020 to $366 billion, despite on-and-off store closures resulting from recurring coronavirus outbreaks and supply chain constraints that have led to more than $9 billion in lost sales. Every product and service segment achieved record-setting revenues with more than 20% growth from previous year results. Much of the year’s success were attributable to a series of new product launches and feature upgrades. The most notable of which included the 5G-enabled family of iPhone 12s and iPhone 13s, as well as the M1-powered MacBook Pro and iPad Pro.</p>\n<p><b>Key Developments in Products</b></p>\n<p>iPhone sales grew by 39% this year, the most amongst other segments, and drove more than half of Apple’s fiscal 2021 revenues. The results were a stark contrast to last year’s slump in demand for the mobile device when consumers braced for pandemic-driven economic uncertainties. iPhone sales are expected to remain robust in coming years as global 5G device upgrades continue to gather pace. The likely launch of a more affordable 5G-enabled iPhone SE in 2022 is also expected to further Apple’s market share gains by&nbsp;attracting switchers&nbsp;from “more than a billion non-premium Android users”, and drive the active installed base to another all-time high. The anticipated momentum is further corroborated by iPhone sales patterns observed in recent quarters following the launch of 5G-enabled iPhone 12s and iPhone 13s, where the number of upgraders and switchers grew by&nbsp;strong double digits. Apple’s strong ties with cell-phone carriers is also expected to drive meaningful iPhone sales contributions in coming years. Reputable wireless carriers in the U.S. like&nbsp;Verizon&nbsp;and&nbsp;AT&amp;T&nbsp;have already been keen on promoting the sale of 5G-enabled devices like the iPhone 12 and iPhone 13 to encourage migration to the 5G network that they have spent billions of dollars on building across the nation. Telecom companies around the world are expected to spend&nbsp;more than $700 billion&nbsp;over the next five years on building-out the 5G network, underscoring significant additional growth opportunities ahead for the iPhone segment as carriers push for the strongest multiyear upgrade cycle in a decade to recoup their investments.</p>\n<p>Mac and iPad sales also grew significantly in fiscal 2021, reaching record revenues of $35.2 billion and $31.9 billion, respectively. Following the introduction of the&nbsp;all-new M1-powered iMac&nbsp;earlier this year, Apple also unveiled the&nbsp;reimagined M1-Pro / M1-Max powered MacBook Pro&nbsp;in October. The custom M1 processors made the newest MacBook “better than any Intel-based device for nearly every productivity use case outside of gaming”. This accordingly drove incredible demand for the portable workstation from a diverse group of consumers, ranging from professional creators and photographers to corporate users and students. The company is estimated to have shipped&nbsp;over 3.2 million units&nbsp;of Mac products during the September quarter, which drove record-setting revenues for the segment, while boosting its rank in global PC sales to fourth place amongst other vendors. The introduction of M1-processors in Apple’s computing products also bolstered its position in capitalizing on the surge in global demand for PCs and multi-purpose tablets by allowing the company to build devices with innovative features that can be seamlessly integrated across its ecosystem of peripheral accessories and services to draw adjacent revenues. With accelerated adoption of hybrid work and study arrangements in the post-pandemic era, global demand for portable workstations like PCs and multi-purpose tablets are expected to remain elevated in coming years – the sectors are expected to grow into a&nbsp;$224.3 billion&nbsp;and$600 billion&nbsp;market, respectively, by 2025, which makes favorable trends for Apple’s Mac and iPad segments.</p>\n<p>Recent speculations on Apple’s intentions to&nbsp;strengthen its in-house chip development capacity&nbsp;will likely further the advancement of its technologies offered in coming years and draw additional demand to its products. The company is currently looking for engineers to build-out its capacity in the development of “wireless radios, radio-frequency integrated circuits, and a wireless system-on-chip (“SoC”)”, as well as “semiconductors for connecting Bluetooth and Wi-Fi”. These developments are expected to further enhance seamless integration across Apple’s devices and increase stickiness to its ecosystem of product and service offerings, making its chip unit one of the company’s “most prized assets”.</p>\n<p><b>Key Developments in Services</b></p>\n<p>On the services front, a strong subscriber base had enabled the segment to hit record-setting revenues of more than $68.4 billion in fiscal 2021, up 27% from the prior year. To date, Apple has garnered more than 745 million paid subscribers across its high-margin service offerings, representing a five-fold increase over the last five years. Apple’s increasing push for a subscription-based business model across its wide variety of service platforms, ranging from Apple Music to iCloud storage solutions, paired with attractive new offerings that address key consumer trends in recent years have been a key driver to the company’s fast-expanding margins. New exciting add-on features introduced for existing service platforms include&nbsp;Spatial Audio and Lossless Audiofor Apple Music and the&nbsp;Apple Music Voice Plan. The new subscription-based offerings are expected to further Apple’s reach to adjacent opportunities stemming from increasing global usage of smartphones, laptops and other advanced home electronic products – for instance, the global music streaming market is expected to expand at a CAGR of 16% towards a&nbsp;projected value of $61 billion&nbsp;over the next five years, underscoring significant growth headroom for Apple Music. And Apple’s latest introduction of the&nbsp;Apple One bundle&nbsp;is expected to be a key contributor to furthering service segment sales in coming years by attracting new users to pay for subscription services that they otherwise would not have had it not been for the bundle discounts.</p>\n<p>Continued growth in market demand for mobile applications will also be a boon to Apple’s fast-growing services segment. The global market for mobile applications is expected to grow at a CAGR of 18.4% and reach a market value of&nbsp;more than $400 billion&nbsp;over the next five years. With AAPL hosting&nbsp;one of the largest and most used app stores&nbsp;in the world, it would be reasonable to assume that related revenues would grow at a similar pace. Despite&nbsp;mounting global regulatory scrutiny&nbsp;over Apple’s alleged antitrust violations with its App Store – the most notable of which stemming from an ongoing&nbsp;legal battle with Epic Games– the company’s continued focus on ensuring user privacy, security, and ease of transactions might have saved the day. According to a survey of 4,000 Apple product users performed by Morgan Stanley across the U.S. and China, most have indicated loyalty to Apple’s App store due to the “value of security, privacy and ease of transactions” provided, despite developers pushing for rights to transact outside of Apple’s ecosystem. Apple’s recent success in&nbsp;delaying App Store changes&nbsp;ordered by U.S. District Judge Yvonne Gonzalez Rogers in&nbsp;September&nbsp;as part of a year-long lawsuit brought against by Epic Games is another sign of the App Store’s continued strength. The company has argued that the court-mandated order to allow App Store users to “buy directly from developers on the web” would be a threat to the security of their privacy.</p>\n<p>Currently, developers are fighting for their rights to have app users transact outside of Apple’s ecosystem, which charges developers a hefty commission fee of up to 30% on all purchases. As Apple continues with its appeal of the ruling, the ultimate court decision on whether App Store changes would need to be implemented could take at least another year. But even with an unfavorable ruling, where Apple would have to allow developers to redirect users to payments outside of its ecosystem and/or lower its in-app purchase commission rate, App Store revenues are only expected to decrease by&nbsp;at most $4 billion per year&nbsp;which will not place a material impact on its valuation prospects. The actual quantified impact might even be less than what the market has forecasted, considering the value that App Store users have ascribed to the level of security and convenience that Apple has offered through the platform.</p>\n<p><b>Key Catalysts Ahead</b></p>\n<p>Apple is undoubtedly a key gateway to bringing emerging technologies to the mainstream due to its massive installed base of devices and related service platform users. And because of this, the highly anticipated launch of cutting-edge products like AR/VR headsets and autonomous vehicles in coming years will likely catapult the stock to new heights. The pioneer of disruptive consumer electronics and devices is expected to launch a&nbsp;VR headset and AR glasses&nbsp;by early 2023, a nascent technology that has been picking up steam in recent months with increasing talks of the metaverse. Similar to most VR headsets already available in the market, Apple’s will feature a 3D display to enable an immersive environment for a variety of activities from gaming to communicating. The differentiating factor will be the company’s plans to implement best-in-class graphics chips in the device to facilitate ultra-high-resolution displays. The impending VR headset will ultimately lay the foundation for its AR glasses, which Apple expects to be the “larger opportunity”.</p>\n<p>Over the next five years, opportunities pertaining to the metaverse are expected to blossom into an&nbsp;$800 billion market. Related software and service sales are expected to drive more than 70% of the projected addressable market, while the remainder will likely be driven by hardware sales. This makes strong tailwinds for Apple, which does not only stand to capitalize on growing metaverse opportunities through the sale of its impending AR/VR headset, but also adjacent revenues pertaining to the usage of related apps, software and service platforms.</p>\n<p>Speculations on Apple’s ongoing development of&nbsp;a self-driving electric car&nbsp;is also expected to materialize into meaningful upsides for the stock within the foreseeable future. The company is now planning to launch the new product category by 2025, at which time the global autonomous vehicle market is expected to reach a value of&nbsp;more than $200 billion. The eventual car will likely feature homages to its existing product portfolio, like an “iPad-like touch screen” infotainment system. And on the technology front, Apple is believed to have completed the development of a custom silicon for powering the vehicle’s autonomous driving capabilities. The newest chips will soon be implemented into its existing fleet of retrofitted SUVs for testing in California according to the state’s DMV, a sign that the impending launch is near.</p>\n<p>While Apple’s current market value may already be reflective of “consistent material revenue contributions from new products and services over time”, additional upsides from the above-mentioned new product category launches are still missing. But this will likely change within the next 12 months as the impending launch of an Apple AR/VR device draws near. Near-term projections on early AR/VR device sales are expected to boost Apple’s valuation by&nbsp;at least $150 billion. And over time when metaverse trends continue to gain mainstream traction, Apple is expected to generate more than $200 billion in annual revenues from the AR/VR segment, which could add another 15% on top of its current market value.</p>\n<p><b>Valuation Prospects and Potential Impacts from the Impending Rate Increases</b></p>\n<p>Adjusting our most recent forecast for Apple’s fiscal 2021 year-end results and December-quarter guidance, our base case projection estimates total net sales of $439.3 billion by the end of fiscal 2022, with further growth towards $668.5 billion by fiscal 2026. The growth assumptions applied across segment revenues in our forecast remains largely unchanged from our&nbsp;most recent analysis&nbsp;on the stock, with additional consideration for management’s near-term outlook on supply constraint impacts and the impending rate hikes. Specifically, lost revenues of $9 billion (i.e. approximately $3 billion during June-quarter and $6 billion during September-quarter) attributable to industry-wide chip shortages and pandemic-driven manufacturing delays during the second half of fiscal 2021 is expected to worsen into the first half of fiscal 2022. While there have been observed improvements to supply chain challenges, continuously robust demand for Apple products is what will drive a higher volume of lost sales in coming quarters. Nonetheless, Apple remains well-positioned for strong fundamentals ahead, which will help to alleviate some of investors’ concerns on valuation due to impending rate hikes.</p>\n<p><img src=\"https://static.tigerbbs.com/b5aa95136cfca6f95b962ea36eadab74\" tg-width=\"640\" tg-height=\"257\" width=\"100%\" height=\"auto\"></p>\n<p><i>i. Base Case Financial Projections:</i></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6585b165abd25fab7d171dd944d05156\" tg-width=\"640\" tg-height=\"316\" width=\"100%\" height=\"auto\"><span>Source: Author, with data from our internal financial forecast (Apple_-_Forecasted_Financial_Information.pdf). Please refer here for further detail on material growth assumptions applied.</span></p>\n<p>Drawing on the above considerations, our 12-month price target for the Apple stock has been revised to $209.43. This represents upside potential of more than 22% based on the last traded price of $171.14 on December 17th.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e88e904b5b900fbcdf4541d856570e2d\" tg-width=\"640\" tg-height=\"230\" width=\"100%\" height=\"auto\"><span>Source: Author, with data from our internal valuation analysis.</span></p>\n<p>The revised price target is derived using a discounted cash flow (“DCF”) analysis over a ten-year discrete period in conjunction with the financial projections updated for Apple’s recent developments as analyzed in earlier sections. Similar to our original valuation analysis, we have applied a WACC of 8% to discount Apple’s projected free cash flows. The discount function is reflective of the company’s risk profile, taking into consideration its current capital structure and strong balance sheet. Apple’s cost of capital for growth is not expected to change significantly as a result of the impending rate hikes, considering a large portion of its existing debt are fixed-rate notes. The company also boasts a consistently robust net cash position, in which management intends to deploy towards additional growth without having to incur incremental capital costs ahead of interest rate increases. This is expected to further cement investors’ confidence in the Apple stock, as they continue their “flight to quality” amidst fear of broader market pressure from rising interest rates.</p>\n<p>The valuation analysis also assumes an exit multiple of 19.8x, which is consistent with current market expectations on Apple’s growth trajectory over the forecasted period. The applied exit multiple assumption could even improve further within the next 12 months, considering the impending launch of new product segments like AR/VR devices and autonomous vehicles, and offset any potential impacts from the upcoming increases to interest rates.</p>\n<p><i>i. Base Case Valuation Analysis:</i></p>\n<p><img src=\"https://static.tigerbbs.com/81f992ef8b2b59ea879f69a7b1e7ad52\" tg-width=\"640\" tg-height=\"300\" width=\"100%\" height=\"auto\"></p>\n<p><i>ii. Sensitivity Analysis:</i></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/da8b21dae04fd263929ab26bd8d83907\" tg-width=\"640\" tg-height=\"337\" width=\"100%\" height=\"auto\"><span>Source: Author, with data from our internal valuation analysis.</span></p>\n<p><b>Conclusion</b></p>\n<p>Based on the foregoing analysis, the anticipated addition of 175 to 200 basis points to the current near-zero Federal Fund Rate over the next two years is not expected to cause material adverse impacts to Apple’s performance from both a fundamental and valuation perspective. Robust global demand for Apple products and services, paired with new innovations are expected to further bolster the company’s fundamental growth prospects. This would accordingly bring additional improvements to Apple’s balance sheet, and further strengthen its position against downward valuation pressures from broader macro headwinds. In fact, increasing demand for quality growth stocks to counter risks resulting from the impending rate hikes might even fuel Apple’s valuation growth momentum. On these considerations, Apple remains one of the best-performing tech stocks to own given its robust uptrend to $3 trillion in the near-term despite impending rate hikes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: The Strongest Shield Against Rate Hikes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: The Strongest Shield Against Rate Hikes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-20 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4475887-apple-stock-aapl-strongest-shield-against-rate-hikes><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nWith inflation running its hottest course in 40 years, the Federal Reserve has decided to accelerate the stimulus tapering schedule and prepare for raising interest rates as early as March.\n...</p>\n\n<a href=\"https://seekingalpha.com/article/4475887-apple-stock-aapl-strongest-shield-against-rate-hikes\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/article/4475887-apple-stock-aapl-strongest-shield-against-rate-hikes","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183475424","content_text":"Summary\n\nWith inflation running its hottest course in 40 years, the Federal Reserve has decided to accelerate the stimulus tapering schedule and prepare for raising interest rates as early as March.\nWhile rate hikes have historically deterred investors from growth stocks due to concerns over eroding valuation prospects, the Apple stock has remained largely resilient.\nApple is expected to realize additional upsides ahead, sustained by robust demand for its existing offerings and new opportunities arising from nascent technologies like AR/VR and autonomous vehicles.\nIts strong net cash position also provides sufficient dry powder to fund additional growth in coming years without incurring additional costs of capital amidst rising interest rates.\nAs such, Apple's bullish thesis remains intact as it approaches a $3 trillion valuation, despite broader market valuation risks ahead.\n\nguvendemir/iStock Unreleased via Getty Images\nAs one of the world’s best performing stocks, Apple(NASDAQ:AAPL) has gained close to 40% this year. The stock, which last peaked at $182.13 not too long ago, is currently less than 7% from being the first U.S. publicly listed company to reach a $3 trillion market value and single-handedly accounts for about 15% of the tech-heavy Nasdaq 100’s performance. Apple’s market value has grown by more than 220x since the late 1990s, buoyed by the company’s continuous ability to capture robust demand for its innovative portfolio of products and services.\nAnd Apple’s strong fundamentals are expected to help the stock defy adverse impacts from the imminent rate hikes beginning next year. With inflation running at its hottest in almost four decades, the Federal Reserve decided Wednesday that it will increase the pace at which it is dialing back on the $120 billion monthly bond repurchasing program from $15 billion per month, which began in November, to $30 billion per month. This would effectively conclude the stimulus program, put in place at the onset of the pandemic, coming March, rather than in July as initially planned. Rate hikes are expected to begin soon after to counter rising price pressures, with Federal Reserve Chair Jerome Powell affirming that the process will only begin after tapering ends and at a gradual pace. The latest dot plot indicates potential for the Federal Fund Rate to lift-off from near-zero beginning early 2022 with three quarter-point increases, plus another three in 2023 and two more in 2024. If materialized, the process would up the funds rate to 2.1% by 2024.\nSource: Bloomberg\nWhile rate hikes typically cause investors to turn risk averse due to concerns over faster erosion of value on future gains and stalled business growth due to rising costs of capital, especially for high-growth stocks, Apple gained close to 3% upon release of the Fed’s update on policy tightening. The stock closed at $179.30 on December 15th, nearing its peak of $182 on Monday. Apple’s rally, along with similar uptrends observed across other mega-cap tech stocks, accordingly drove intra-day gains of 2.4% for the Nasdaq 100 following the Federal Reserve’s update, indicating investors’ preference to park their money in companies with robust growth prospects to counter risks from the impending rate increases.\nWith the coming holiday season a boon for Apple’s December-quarter sales, the stock’s valuation is expected to enter in the $3 trillion territory sooner than expected. Continued robust demand observed across Apple’s entire product line, generous share buy-backs, and additional revenue contributions expected within the foreseeable future resulting from new, cutting-edge products will also be key catalysts to support the company’s persistently strong fundamentals and keep the stock’s valuation above $3 trillion despite the impending rate hikes. Considering recent developments to the broader market and Apple’s growth prospects, we are raising our 12-month price target for the stock to $209.43.\nFY 2021 Overview and Recap of Fundamental Prospects\nFiscal 2021 was a big year for Apple. The company’s revenues for the year grew 33% from fiscal 2020 to $366 billion, despite on-and-off store closures resulting from recurring coronavirus outbreaks and supply chain constraints that have led to more than $9 billion in lost sales. Every product and service segment achieved record-setting revenues with more than 20% growth from previous year results. Much of the year’s success were attributable to a series of new product launches and feature upgrades. The most notable of which included the 5G-enabled family of iPhone 12s and iPhone 13s, as well as the M1-powered MacBook Pro and iPad Pro.\nKey Developments in Products\niPhone sales grew by 39% this year, the most amongst other segments, and drove more than half of Apple’s fiscal 2021 revenues. The results were a stark contrast to last year’s slump in demand for the mobile device when consumers braced for pandemic-driven economic uncertainties. iPhone sales are expected to remain robust in coming years as global 5G device upgrades continue to gather pace. The likely launch of a more affordable 5G-enabled iPhone SE in 2022 is also expected to further Apple’s market share gains by attracting switchers from “more than a billion non-premium Android users”, and drive the active installed base to another all-time high. The anticipated momentum is further corroborated by iPhone sales patterns observed in recent quarters following the launch of 5G-enabled iPhone 12s and iPhone 13s, where the number of upgraders and switchers grew by strong double digits. Apple’s strong ties with cell-phone carriers is also expected to drive meaningful iPhone sales contributions in coming years. Reputable wireless carriers in the U.S. like Verizon and AT&T have already been keen on promoting the sale of 5G-enabled devices like the iPhone 12 and iPhone 13 to encourage migration to the 5G network that they have spent billions of dollars on building across the nation. Telecom companies around the world are expected to spend more than $700 billion over the next five years on building-out the 5G network, underscoring significant additional growth opportunities ahead for the iPhone segment as carriers push for the strongest multiyear upgrade cycle in a decade to recoup their investments.\nMac and iPad sales also grew significantly in fiscal 2021, reaching record revenues of $35.2 billion and $31.9 billion, respectively. Following the introduction of the all-new M1-powered iMac earlier this year, Apple also unveiled the reimagined M1-Pro / M1-Max powered MacBook Pro in October. The custom M1 processors made the newest MacBook “better than any Intel-based device for nearly every productivity use case outside of gaming”. This accordingly drove incredible demand for the portable workstation from a diverse group of consumers, ranging from professional creators and photographers to corporate users and students. The company is estimated to have shipped over 3.2 million units of Mac products during the September quarter, which drove record-setting revenues for the segment, while boosting its rank in global PC sales to fourth place amongst other vendors. The introduction of M1-processors in Apple’s computing products also bolstered its position in capitalizing on the surge in global demand for PCs and multi-purpose tablets by allowing the company to build devices with innovative features that can be seamlessly integrated across its ecosystem of peripheral accessories and services to draw adjacent revenues. With accelerated adoption of hybrid work and study arrangements in the post-pandemic era, global demand for portable workstations like PCs and multi-purpose tablets are expected to remain elevated in coming years – the sectors are expected to grow into a $224.3 billion and$600 billion market, respectively, by 2025, which makes favorable trends for Apple’s Mac and iPad segments.\nRecent speculations on Apple’s intentions to strengthen its in-house chip development capacity will likely further the advancement of its technologies offered in coming years and draw additional demand to its products. The company is currently looking for engineers to build-out its capacity in the development of “wireless radios, radio-frequency integrated circuits, and a wireless system-on-chip (“SoC”)”, as well as “semiconductors for connecting Bluetooth and Wi-Fi”. These developments are expected to further enhance seamless integration across Apple’s devices and increase stickiness to its ecosystem of product and service offerings, making its chip unit one of the company’s “most prized assets”.\nKey Developments in Services\nOn the services front, a strong subscriber base had enabled the segment to hit record-setting revenues of more than $68.4 billion in fiscal 2021, up 27% from the prior year. To date, Apple has garnered more than 745 million paid subscribers across its high-margin service offerings, representing a five-fold increase over the last five years. Apple’s increasing push for a subscription-based business model across its wide variety of service platforms, ranging from Apple Music to iCloud storage solutions, paired with attractive new offerings that address key consumer trends in recent years have been a key driver to the company’s fast-expanding margins. New exciting add-on features introduced for existing service platforms include Spatial Audio and Lossless Audiofor Apple Music and the Apple Music Voice Plan. The new subscription-based offerings are expected to further Apple’s reach to adjacent opportunities stemming from increasing global usage of smartphones, laptops and other advanced home electronic products – for instance, the global music streaming market is expected to expand at a CAGR of 16% towards a projected value of $61 billion over the next five years, underscoring significant growth headroom for Apple Music. And Apple’s latest introduction of the Apple One bundle is expected to be a key contributor to furthering service segment sales in coming years by attracting new users to pay for subscription services that they otherwise would not have had it not been for the bundle discounts.\nContinued growth in market demand for mobile applications will also be a boon to Apple’s fast-growing services segment. The global market for mobile applications is expected to grow at a CAGR of 18.4% and reach a market value of more than $400 billion over the next five years. With AAPL hosting one of the largest and most used app stores in the world, it would be reasonable to assume that related revenues would grow at a similar pace. Despite mounting global regulatory scrutiny over Apple’s alleged antitrust violations with its App Store – the most notable of which stemming from an ongoing legal battle with Epic Games– the company’s continued focus on ensuring user privacy, security, and ease of transactions might have saved the day. According to a survey of 4,000 Apple product users performed by Morgan Stanley across the U.S. and China, most have indicated loyalty to Apple’s App store due to the “value of security, privacy and ease of transactions” provided, despite developers pushing for rights to transact outside of Apple’s ecosystem. Apple’s recent success in delaying App Store changes ordered by U.S. District Judge Yvonne Gonzalez Rogers in September as part of a year-long lawsuit brought against by Epic Games is another sign of the App Store’s continued strength. The company has argued that the court-mandated order to allow App Store users to “buy directly from developers on the web” would be a threat to the security of their privacy.\nCurrently, developers are fighting for their rights to have app users transact outside of Apple’s ecosystem, which charges developers a hefty commission fee of up to 30% on all purchases. As Apple continues with its appeal of the ruling, the ultimate court decision on whether App Store changes would need to be implemented could take at least another year. But even with an unfavorable ruling, where Apple would have to allow developers to redirect users to payments outside of its ecosystem and/or lower its in-app purchase commission rate, App Store revenues are only expected to decrease by at most $4 billion per year which will not place a material impact on its valuation prospects. The actual quantified impact might even be less than what the market has forecasted, considering the value that App Store users have ascribed to the level of security and convenience that Apple has offered through the platform.\nKey Catalysts Ahead\nApple is undoubtedly a key gateway to bringing emerging technologies to the mainstream due to its massive installed base of devices and related service platform users. And because of this, the highly anticipated launch of cutting-edge products like AR/VR headsets and autonomous vehicles in coming years will likely catapult the stock to new heights. The pioneer of disruptive consumer electronics and devices is expected to launch a VR headset and AR glasses by early 2023, a nascent technology that has been picking up steam in recent months with increasing talks of the metaverse. Similar to most VR headsets already available in the market, Apple’s will feature a 3D display to enable an immersive environment for a variety of activities from gaming to communicating. The differentiating factor will be the company’s plans to implement best-in-class graphics chips in the device to facilitate ultra-high-resolution displays. The impending VR headset will ultimately lay the foundation for its AR glasses, which Apple expects to be the “larger opportunity”.\nOver the next five years, opportunities pertaining to the metaverse are expected to blossom into an $800 billion market. Related software and service sales are expected to drive more than 70% of the projected addressable market, while the remainder will likely be driven by hardware sales. This makes strong tailwinds for Apple, which does not only stand to capitalize on growing metaverse opportunities through the sale of its impending AR/VR headset, but also adjacent revenues pertaining to the usage of related apps, software and service platforms.\nSpeculations on Apple’s ongoing development of a self-driving electric car is also expected to materialize into meaningful upsides for the stock within the foreseeable future. The company is now planning to launch the new product category by 2025, at which time the global autonomous vehicle market is expected to reach a value of more than $200 billion. The eventual car will likely feature homages to its existing product portfolio, like an “iPad-like touch screen” infotainment system. And on the technology front, Apple is believed to have completed the development of a custom silicon for powering the vehicle’s autonomous driving capabilities. The newest chips will soon be implemented into its existing fleet of retrofitted SUVs for testing in California according to the state’s DMV, a sign that the impending launch is near.\nWhile Apple’s current market value may already be reflective of “consistent material revenue contributions from new products and services over time”, additional upsides from the above-mentioned new product category launches are still missing. But this will likely change within the next 12 months as the impending launch of an Apple AR/VR device draws near. Near-term projections on early AR/VR device sales are expected to boost Apple’s valuation by at least $150 billion. And over time when metaverse trends continue to gain mainstream traction, Apple is expected to generate more than $200 billion in annual revenues from the AR/VR segment, which could add another 15% on top of its current market value.\nValuation Prospects and Potential Impacts from the Impending Rate Increases\nAdjusting our most recent forecast for Apple’s fiscal 2021 year-end results and December-quarter guidance, our base case projection estimates total net sales of $439.3 billion by the end of fiscal 2022, with further growth towards $668.5 billion by fiscal 2026. The growth assumptions applied across segment revenues in our forecast remains largely unchanged from our most recent analysis on the stock, with additional consideration for management’s near-term outlook on supply constraint impacts and the impending rate hikes. Specifically, lost revenues of $9 billion (i.e. approximately $3 billion during June-quarter and $6 billion during September-quarter) attributable to industry-wide chip shortages and pandemic-driven manufacturing delays during the second half of fiscal 2021 is expected to worsen into the first half of fiscal 2022. While there have been observed improvements to supply chain challenges, continuously robust demand for Apple products is what will drive a higher volume of lost sales in coming quarters. Nonetheless, Apple remains well-positioned for strong fundamentals ahead, which will help to alleviate some of investors’ concerns on valuation due to impending rate hikes.\n\ni. Base Case Financial Projections:\nSource: Author, with data from our internal financial forecast (Apple_-_Forecasted_Financial_Information.pdf). Please refer here for further detail on material growth assumptions applied.\nDrawing on the above considerations, our 12-month price target for the Apple stock has been revised to $209.43. This represents upside potential of more than 22% based on the last traded price of $171.14 on December 17th.\nSource: Author, with data from our internal valuation analysis.\nThe revised price target is derived using a discounted cash flow (“DCF”) analysis over a ten-year discrete period in conjunction with the financial projections updated for Apple’s recent developments as analyzed in earlier sections. Similar to our original valuation analysis, we have applied a WACC of 8% to discount Apple’s projected free cash flows. The discount function is reflective of the company’s risk profile, taking into consideration its current capital structure and strong balance sheet. Apple’s cost of capital for growth is not expected to change significantly as a result of the impending rate hikes, considering a large portion of its existing debt are fixed-rate notes. The company also boasts a consistently robust net cash position, in which management intends to deploy towards additional growth without having to incur incremental capital costs ahead of interest rate increases. This is expected to further cement investors’ confidence in the Apple stock, as they continue their “flight to quality” amidst fear of broader market pressure from rising interest rates.\nThe valuation analysis also assumes an exit multiple of 19.8x, which is consistent with current market expectations on Apple’s growth trajectory over the forecasted period. The applied exit multiple assumption could even improve further within the next 12 months, considering the impending launch of new product segments like AR/VR devices and autonomous vehicles, and offset any potential impacts from the upcoming increases to interest rates.\ni. Base Case Valuation Analysis:\n\nii. Sensitivity Analysis:\nSource: Author, with data from our internal valuation analysis.\nConclusion\nBased on the foregoing analysis, the anticipated addition of 175 to 200 basis points to the current near-zero Federal Fund Rate over the next two years is not expected to cause material adverse impacts to Apple’s performance from both a fundamental and valuation perspective. Robust global demand for Apple products and services, paired with new innovations are expected to further bolster the company’s fundamental growth prospects. This would accordingly bring additional improvements to Apple’s balance sheet, and further strengthen its position against downward valuation pressures from broader macro headwinds. In fact, increasing demand for quality growth stocks to counter risks resulting from the impending rate hikes might even fuel Apple’s valuation growth momentum. On these considerations, Apple remains one of the best-performing tech stocks to own given its robust uptrend to $3 trillion in the near-term despite impending rate hikes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":706,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604260667,"gmtCreate":1639403813827,"gmtModify":1639403991447,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Wow beyond my expectation ! GoApple go!","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Wow beyond my expectation ! GoApple go!","text":"$Apple(AAPL)$Wow beyond my expectation ! GoApple go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604260667","isVote":1,"tweetType":1,"viewCount":766,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602289077,"gmtCreate":1639025887863,"gmtModify":1639025910576,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"Apple is premium stock. So when Low get in to keep for the long run. Strong brand and innovativewith sight on EV market expanding their VP to embrace a wider lifestyle&nbsp;market.","listText":"Apple is premium stock. So when Low get in to keep for the long run. Strong brand and innovativewith sight on EV market expanding their VP to embrace a wider lifestyle&nbsp;market.","text":"Apple is premium stock. So when Low get in to keep for the long run. Strong brand and innovativewith sight on EV market expanding their VP to embrace a wider lifestyle market.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602289077","isVote":1,"tweetType":1,"viewCount":813,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606784546,"gmtCreate":1638928527407,"gmtModify":1638928527480,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>Always good to buy some and keep.This is a premium airline stock that has strong government support in a very structured and organised country. When things open up this will fly!","listText":"<a href=\"https://laohu8.com/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>Always good to buy some and keep.This is a premium airline stock that has strong government support in a very structured and organised country. When things open up this will fly!","text":"$SINGAPORE AIRLINES LTD(C6L.SI)$Always good to buy some and keep.This is a premium airline stock that has strong government support in a very structured and organised country. When things open up this will fly!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":3,"repostSize":1,"link":"https://laohu8.com/post/606784546","isVote":1,"tweetType":1,"viewCount":1739,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842023509,"gmtCreate":1636121445856,"gmtModify":1636121445941,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"This means long term growth!!!!","listText":"This means long term growth!!!!","text":"This means long term growth!!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842023509","repostId":"1166866310","repostType":2,"repost":{"id":"1166866310","kind":"news","pubTimestamp":1636112660,"share":"https://www.laohu8.com/m/news/1166866310?lang=&edition=full","pubTime":"2021-11-05 19:44","market":"us","language":"en","title":"Pfizer Develops Covid Pill That Cuts Hospitalizations and Deaths by 89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166866310","media":"Bloomberg","summary":"Drug reduced Covid hospitalizations by 89% in clinical trial\nPfizer shares surge 11%; Merck pill awa","content":"<ul>\n <li>Drug reduced Covid hospitalizations by 89% in clinical trial</li>\n <li>Pfizer shares surge 11%; Merck pill awaiting U.S. approval</li>\n</ul>\n<p>Pfizer Inc.&nbsp;said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%, a result that has the potential to upend how the disease caused by the coronavirus is treated and alter the course of the pandemic. The shares surged 11%.</p>\n<p>The drugmaker said in a statement on Friday that it was no longer taking new patients in a clinical trial of the treatment “due to the overwhelming efficacy” and planned to submit the findings to U.S. regulatory authorities for emergency authorization as soon as possible.</p>\n<p>The results mean there are now two promising candidates for treating Covid-19 patients early in the course of the disease. Last month,Merck &amp; Co.&nbsp;and partner Ridgeback Biotherapeutics LP submitted their experimental pill to regulators after a study showed it slashed the risk of getting seriously ill or dying&nbsp;by half&nbsp;in patients with mild-to-moderate Covid-19.</p>\n<p>Pfizer gained 11% in premarket U.S. trading, while Merck fell 6.6%. Some vaccine makers lost ground, with&nbsp;Moderna Inc&nbsp;.down 4.5% and Pfizer partner&nbsp;BioNTech&nbsp;SE slipping 4% in German trading.</p>\n<p>A pill that could be taken at home at the first sign of symptoms is a crucial tool for taming the Covid-19 crisis globally, so long as it’s widely available. A Pfizer spokesperson said submissions to other regulatory agencies will occur shortly after the U.S. filing.</p>\n<p>In Pfizer’s trial of 1,219 unvaccinated adults, five days of treatment with its drug dramatically reduced the rate of hospitalization when it was started within either three days or five days of symptom onset, the company said. The drug, Paxlovid, binds to an enzyme called a protease to stop the virus from replicating itself. Some drugs for HIV work in a similar way.</p>\n<p>Overall, just 0.8% of people who started treatment within three days of getting sick ended up in the hospital and no one died, while 7% of people who got a placebo in that window were later hospitalized or died. Similar results were found when the drug was started within five days of symptom onset. The result, which hasn’t been published in a medical journal, was highly statistically significant, Pfizer said.</p>\n<p><b>Acute Need</b></p>\n<p>Current treatment options for Covid aren’t ideal. Monoclonal antibodies from companies like&nbsp;Regeneron Pharmaceuticals Inc.&nbsp;and&nbsp;Eli Lilly &amp; Co.&nbsp;reduce hospitalizations, but the infusions are hard to manufacture and must be given in a medical office, adding to the strain on health systems.</p>\n<p>Other medications like&nbsp;Gilead Sciences Inc.’s remdesivir are used to treat much sicker people who are already in the hospital. Low-cost steroid dexamethasone, while very effective, is usually only given to gravely ill patients.</p>\n<p>The need for a pill is so acute that Merck has&nbsp;already agreed&nbsp;to allow generic drugmakers to apply for licenses to make its treatment for more than 100 low- and middle-income nations, before it has even been cleared in the U.S. The U.K.’s drug regulators became the first in the world&nbsp;to greenlight&nbsp;Merck’s drug Thursday after a swift review.</p>\n<p>Now Pfizer’s pill, which works by a different mechanism, appears to have produced even better results in high-risk patients. The trial was stopped early by independent monitors because the effect was so impressive.</p>\n<p>“We are really over the moon that we did see such high efficacy in this study. It has tremendous implications for patients globally,” said Annaliesa Anderson, chief scientific officer for Pfizer’s hospitals business unit, which includes its antiviral work.</p>\n<p>In addition to the current trial in high-risk patients, Pfizer is also testing the drug in standard-risk patients, a study that included some vaccinated people who had breakthrough infections.</p>\n<p>In a third large trial, Pfizer is exploring if the drug could be used as a prophylactic medicine for people who live with someone who has come down with Covid-19, meaning a person would take the drug to avoid contracting the virus.</p>\n<p><b>Old Molecule</b></p>\n<p>The pill was internally developed by Pfizer researchers in the U.S. and U.K. During the early pandemic shutdowns, the scientists agreed to come back to their labs in an urgent effort to develop anti-Covid pills, Anderson said. Company researchers “worked around the clock to design this molecule” in a highly-compressed timeframe, she said.</p>\n<p>They dusted off an old experimental antiviral drug that Pfizer had developed after the original SARS epidemic, a coronavirus cousin to Covid-19 that killed about 800 people starting in late 2002. The old drug needed to be administered intravenously. But by July of last year, the Pfizer researchers tweaked the original molecule and came up with a new compound that turned out to be highly potent against Covid-19 and other coronaviruses in the test tube -- and could be used as a pill.</p>\n<p>The Pfizer drug works to block a crucial enzyme that the Covid-19 virus needs to replicate. It is taken twice a day for five days and used in combination with a second medicine called ritonavir that helps the Pfizer compound stay in the bloodstream longer.</p>\n<p>Pfizer said it planned to offer the antiviral therapy through a tiered pricing approach during the pandemic. High and upper-middle income countries will pay more than lower income countries, it said. The drugmaker didn’t say exactly how much it would charge.</p>\n<p>A Pfizer spokesperson said the company currently expects to produce more than 180,000 packs of the drug by the end of this year, and anticipates making at least 50 million packs by the end of 2022, with 21 million produced in the first half of the year.</p>\n<p></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Develops Covid Pill That Cuts Hospitalizations and Deaths by 89%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Develops Covid Pill That Cuts Hospitalizations and Deaths by 89%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 19:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-to-seek-u-s-nod-for-covid-pill-after-strong-results?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Drug reduced Covid hospitalizations by 89% in clinical trial\nPfizer shares surge 11%; Merck pill awaiting U.S. approval\n\nPfizer Inc. said its Covid-19 pill reduced hospitalizations and deaths in high-...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-to-seek-u-s-nod-for-covid-pill-after-strong-results?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-to-seek-u-s-nod-for-covid-pill-after-strong-results?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166866310","content_text":"Drug reduced Covid hospitalizations by 89% in clinical trial\nPfizer shares surge 11%; Merck pill awaiting U.S. approval\n\nPfizer Inc. said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%, a result that has the potential to upend how the disease caused by the coronavirus is treated and alter the course of the pandemic. The shares surged 11%.\nThe drugmaker said in a statement on Friday that it was no longer taking new patients in a clinical trial of the treatment “due to the overwhelming efficacy” and planned to submit the findings to U.S. regulatory authorities for emergency authorization as soon as possible.\nThe results mean there are now two promising candidates for treating Covid-19 patients early in the course of the disease. Last month,Merck & Co. and partner Ridgeback Biotherapeutics LP submitted their experimental pill to regulators after a study showed it slashed the risk of getting seriously ill or dying by half in patients with mild-to-moderate Covid-19.\nPfizer gained 11% in premarket U.S. trading, while Merck fell 6.6%. Some vaccine makers lost ground, with Moderna Inc .down 4.5% and Pfizer partner BioNTech SE slipping 4% in German trading.\nA pill that could be taken at home at the first sign of symptoms is a crucial tool for taming the Covid-19 crisis globally, so long as it’s widely available. A Pfizer spokesperson said submissions to other regulatory agencies will occur shortly after the U.S. filing.\nIn Pfizer’s trial of 1,219 unvaccinated adults, five days of treatment with its drug dramatically reduced the rate of hospitalization when it was started within either three days or five days of symptom onset, the company said. The drug, Paxlovid, binds to an enzyme called a protease to stop the virus from replicating itself. Some drugs for HIV work in a similar way.\nOverall, just 0.8% of people who started treatment within three days of getting sick ended up in the hospital and no one died, while 7% of people who got a placebo in that window were later hospitalized or died. Similar results were found when the drug was started within five days of symptom onset. The result, which hasn’t been published in a medical journal, was highly statistically significant, Pfizer said.\nAcute Need\nCurrent treatment options for Covid aren’t ideal. Monoclonal antibodies from companies like Regeneron Pharmaceuticals Inc. and Eli Lilly & Co. reduce hospitalizations, but the infusions are hard to manufacture and must be given in a medical office, adding to the strain on health systems.\nOther medications like Gilead Sciences Inc.’s remdesivir are used to treat much sicker people who are already in the hospital. Low-cost steroid dexamethasone, while very effective, is usually only given to gravely ill patients.\nThe need for a pill is so acute that Merck has already agreed to allow generic drugmakers to apply for licenses to make its treatment for more than 100 low- and middle-income nations, before it has even been cleared in the U.S. The U.K.’s drug regulators became the first in the world to greenlight Merck’s drug Thursday after a swift review.\nNow Pfizer’s pill, which works by a different mechanism, appears to have produced even better results in high-risk patients. The trial was stopped early by independent monitors because the effect was so impressive.\n“We are really over the moon that we did see such high efficacy in this study. It has tremendous implications for patients globally,” said Annaliesa Anderson, chief scientific officer for Pfizer’s hospitals business unit, which includes its antiviral work.\nIn addition to the current trial in high-risk patients, Pfizer is also testing the drug in standard-risk patients, a study that included some vaccinated people who had breakthrough infections.\nIn a third large trial, Pfizer is exploring if the drug could be used as a prophylactic medicine for people who live with someone who has come down with Covid-19, meaning a person would take the drug to avoid contracting the virus.\nOld Molecule\nThe pill was internally developed by Pfizer researchers in the U.S. and U.K. During the early pandemic shutdowns, the scientists agreed to come back to their labs in an urgent effort to develop anti-Covid pills, Anderson said. Company researchers “worked around the clock to design this molecule” in a highly-compressed timeframe, she said.\nThey dusted off an old experimental antiviral drug that Pfizer had developed after the original SARS epidemic, a coronavirus cousin to Covid-19 that killed about 800 people starting in late 2002. The old drug needed to be administered intravenously. But by July of last year, the Pfizer researchers tweaked the original molecule and came up with a new compound that turned out to be highly potent against Covid-19 and other coronaviruses in the test tube -- and could be used as a pill.\nThe Pfizer drug works to block a crucial enzyme that the Covid-19 virus needs to replicate. It is taken twice a day for five days and used in combination with a second medicine called ritonavir that helps the Pfizer compound stay in the bloodstream longer.\nPfizer said it planned to offer the antiviral therapy through a tiered pricing approach during the pandemic. High and upper-middle income countries will pay more than lower income countries, it said. The drugmaker didn’t say exactly how much it would charge.\nA Pfizer spokesperson said the company currently expects to produce more than 180,000 packs of the drug by the end of this year, and anticipates making at least 50 million packs by the end of 2022, with 21 million produced in the first half of the year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848476426,"gmtCreate":1636024880577,"gmtModify":1636024880671,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"Trying market now","listText":"Trying market now","text":"Trying market now","images":[{"img":"https://static.tigerbbs.com/a2b0fe2a3113ff5d31962e4b31800c6e","width":"1242","height":"2688"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848476426","isVote":1,"tweetType":1,"viewCount":678,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848470522,"gmtCreate":1636024229209,"gmtModify":1636024229298,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Betting on Pfizer to grow!","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Betting on Pfizer to grow!","text":"$Pfizer(PFE)$Betting on Pfizer to grow!","images":[{"img":"https://static.tigerbbs.com/cf5b996d077112a03e94c73b72d75e49","width":"1125","height":"2711"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/848470522","isVote":1,"tweetType":1,"viewCount":752,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848447653,"gmtCreate":1636024147303,"gmtModify":1636024147428,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Is good place to go in now . Covid will be around for another 5 years… no matter what we do.","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Is good place to go in now . Covid will be around for another 5 years… no matter what we do.","text":"$Pfizer(PFE)$Is good place to go in now . Covid will be around for another 5 years… no matter what we do.","images":[{"img":"https://static.tigerbbs.com/f52a10ae1081e03d560e5ab9491273f2","width":"1125","height":"2793"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848447653","isVote":1,"tweetType":1,"viewCount":508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":880321372,"gmtCreate":1631021697096,"gmtModify":1632904552820,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"Apple will be good for next 6 months&nbsp;","listText":"Apple will be good for next 6 months&nbsp;","text":"Apple will be good for next 6 months","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/880321372","repostId":"1170276114","repostType":2,"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811434410,"gmtCreate":1630335533030,"gmtModify":1704958740532,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"Still good to go… target maybe can be 45","listText":"Still good to go… target maybe can be 45","text":"Still good to go… target maybe can be 45","images":[{"img":"https://static.tigerbbs.com/c7713ad8e358a483e2fff4043469478b","width":"1125","height":"3314"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/811434410","isVote":1,"tweetType":1,"viewCount":270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":819812155,"gmtCreate":1630053811577,"gmtModify":1704955236365,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"Time to go in at its lowest","listText":"Time to go in at its lowest","text":"Time to go in at its lowest","images":[{"img":"https://static.tigerbbs.com/f95d7e10867a186a145ced5d74936b71","width":"1125","height":"3395"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819812155","isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":819832406,"gmtCreate":1630053110505,"gmtModify":1704955221516,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"Interest pop up!","listText":"Interest pop up!","text":"Interest pop up!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819832406","repostId":"1105977007","repostType":4,"isVote":1,"tweetType":1,"viewCount":56,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899736198,"gmtCreate":1628214410714,"gmtModify":1633752544292,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"AMD consolidating stock price to earnings results. If&nbsp;chip shortage prolong … prices will start to rise","listText":"AMD consolidating stock price to earnings results. If&nbsp;chip shortage prolong … prices will start to rise","text":"AMD consolidating stock price to earnings results. If chip shortage prolong … prices will start to rise","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/899736198","isVote":1,"tweetType":1,"viewCount":80,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801806323,"gmtCreate":1627494476862,"gmtModify":1631885479295,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>Good to go in… chip shortage will rebound","listText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>Good to go in… chip shortage will rebound","text":"$Intel(INTC)$Good to go in… chip shortage will rebound","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/801806323","isVote":1,"tweetType":1,"viewCount":44,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809415390,"gmtCreate":1627386711810,"gmtModify":1633765516092,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089970209759400","authorIdStr":"4089970209759400"},"themes":[],"htmlText":"What is paper accou t for ?","listText":"What is paper accou t for ?","text":"What is paper accou t for ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/809415390","isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":606784546,"gmtCreate":1638928527407,"gmtModify":1638928527480,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>Always good to buy some and keep.This is a premium airline stock that has strong government support in a very structured and organised country. When things open up this will fly!","listText":"<a href=\"https://laohu8.com/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>Always good to buy some and keep.This is a premium airline stock that has strong government support in a very structured and organised country. When things open up this will fly!","text":"$SINGAPORE AIRLINES LTD(C6L.SI)$Always good to buy some and keep.This is a premium airline stock that has strong government support in a very structured and organised country. When things open up this will fly!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":3,"repostSize":1,"link":"https://laohu8.com/post/606784546","isVote":1,"tweetType":1,"viewCount":1739,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848470522,"gmtCreate":1636024229209,"gmtModify":1636024229298,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Betting on Pfizer to grow!","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Betting on Pfizer to grow!","text":"$Pfizer(PFE)$Betting on Pfizer to grow!","images":[{"img":"https://static.tigerbbs.com/cf5b996d077112a03e94c73b72d75e49","width":"1125","height":"2711"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/848470522","isVote":1,"tweetType":1,"viewCount":752,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":602289077,"gmtCreate":1639025887863,"gmtModify":1639025910576,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"Apple is premium stock. So when Low get in to keep for the long run. Strong brand and innovativewith sight on EV market expanding their VP to embrace a wider lifestyle&nbsp;market.","listText":"Apple is premium stock. So when Low get in to keep for the long run. Strong brand and innovativewith sight on EV market expanding their VP to embrace a wider lifestyle&nbsp;market.","text":"Apple is premium stock. So when Low get in to keep for the long run. Strong brand and innovativewith sight on EV market expanding their VP to embrace a wider lifestyle market.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602289077","isVote":1,"tweetType":1,"viewCount":813,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604260667,"gmtCreate":1639403813827,"gmtModify":1639403991447,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Wow beyond my expectation ! GoApple go!","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Wow beyond my expectation ! GoApple go!","text":"$Apple(AAPL)$Wow beyond my expectation ! GoApple go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604260667","isVote":1,"tweetType":1,"viewCount":766,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848447653,"gmtCreate":1636024147303,"gmtModify":1636024147428,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Is good place to go in now . Covid will be around for another 5 years… no matter what we do.","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Is good place to go in now . Covid will be around for another 5 years… no matter what we do.","text":"$Pfizer(PFE)$Is good place to go in now . Covid will be around for another 5 years… no matter what we do.","images":[{"img":"https://static.tigerbbs.com/f52a10ae1081e03d560e5ab9491273f2","width":"1125","height":"2793"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848447653","isVote":1,"tweetType":1,"viewCount":508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":693318282,"gmtCreate":1639970145691,"gmtModify":1639971034307,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"It started with a cult following. The innovation has simmer abit compared to previous Job’s&nbsp;years but I am hopeful that some new breakthrough willcontinue in the communication space.&nbsp;They did well in the “wearable” when they make I watch a potential medical grade device for cardio.Everyone is into AR but actually making it immersive and ambient so that adoption is intuitive would require the likes of Job or Ian or Elon to drive the “work of Perfection “ in innovation and design.With the bourse it has, I agree that it’s a good haven at a right price and a good chance for upsideif they put more weight into their innovation.","listText":"It started with a cult following. The innovation has simmer abit compared to previous Job’s&nbsp;years but I am hopeful that some new breakthrough willcontinue in the communication space.&nbsp;They did well in the “wearable” when they make I watch a potential medical grade device for cardio.Everyone is into AR but actually making it immersive and ambient so that adoption is intuitive would require the likes of Job or Ian or Elon to drive the “work of Perfection “ in innovation and design.With the bourse it has, I agree that it’s a good haven at a right price and a good chance for upsideif they put more weight into their innovation.","text":"It started with a cult following. The innovation has simmer abit compared to previous Job’s years but I am hopeful that some new breakthrough willcontinue in the communication space. They did well in the “wearable” when they make I watch a potential medical grade device for cardio.Everyone is into AR but actually making it immersive and ambient so that adoption is intuitive would require the likes of Job or Ian or Elon to drive the “work of Perfection “ in innovation and design.With the bourse it has, I agree that it’s a good haven at a right price and a good chance for upsideif they put more weight into their innovation.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693318282","repostId":"1183475424","repostType":4,"isVote":1,"tweetType":1,"viewCount":706,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":880321372,"gmtCreate":1631021697096,"gmtModify":1632904552820,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"Apple will be good for next 6 months&nbsp;","listText":"Apple will be good for next 6 months&nbsp;","text":"Apple will be good for next 6 months","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/880321372","repostId":"1170276114","repostType":2,"repost":{"id":"1170276114","kind":"news","pubTimestamp":1631021014,"share":"https://www.laohu8.com/m/news/1170276114?lang=&edition=full","pubTime":"2021-09-07 21:23","market":"us","language":"en","title":"Apple Stock: $3 Trillion Is Next, Says This Expert","url":"https://stock-news.laohu8.com/highlight/detail?id=1170276114","media":"The Street","summary":"Wedbush’s Dan Ives has made a bold prediction: Apple stock will be valued at $3 trillion within six ","content":"<blockquote>\n <b>Wedbush’s Dan Ives has made a bold prediction: <a href=\"https://laohu8.com/S/AAPL\">Apple</a> stock will be valued at $3 trillion within six to nine months. Here is what supports his bullish thesis.</b>\n</blockquote>\n<p>Wedbush analyst Dan Ives, whom&nbsp;the Apple Maven interviewed a few weeks ago, is not letting off the gas. In his opinion, <a href=\"https://laohu8.com/S/AAPL\">Apple</a> stock-Get Apple Inc. (AAPL) Report&nbsp;will be valued at $3 trillion within the next six to nine months – thus becoming the first company to ever reach this valuation milestone.</p>\n<p>The Apple Maven reviews Mr. Ives’ bullish thesis and the key factors that support it. Lastly, I present <a href=\"https://laohu8.com/S/AONE.U\">one</a> rare instance in which I disagree with the Wedbush analyst.</p>\n<p><b>It starts with the super cycle</b></p>\n<p>During his&nbsp;interview&nbsp;with Bloomberg, Dan Ives explained why Apple stock should be worth $3 trillion soon, up 18% from $2.55 trillion today. At the core of the bullish case is what the analyst calls the “elongated iPhone super cycle”.</p>\n<p>In my conversation with Dan, he explained that Wall Street underestimates the depth of the upgrade cycle that the iPhone 12 has merely kickstarted. Rather than one wave, he sees multiple iterations of smartphone users buying Apple’s new devices over the next few years. His quote:</p>\n<blockquote>\n “If you look at it, we still have 25% of the base that has not upgraded their iPhones in the last three and a half years. 5G does not get fully embraced for the next two or three years, until the networks are built out. In <a href=\"https://laohu8.com/S/CAAS\">China</a> [where the 5G infrastructure is further ahead], the iPhone 12, especially the larger Pro versions, really sold extremely well.”\n</blockquote>\n<p><b>Services and innovation</b></p>\n<p>But not all is about iPhone sales upside. Dan also mentioned two other important factors that support his bullishness: services and technological innovations.</p>\n<p>On the former, the analyst believes that this massive segment, which produces $65 billion in revenues per year and grows at a pace of 20%-plus, is worth $1.4 trillion. The 20x implied price-to-sales valuation may seem too rich, but less so if one considers the enviable 65% op margins and solid growth prospects.</p>\n<p>Regarding the latter, Dan points out that Apple continues to impress on the technological innovation front – something that has not been left in the rearview mirror, as some skeptics believe. I agree with this take, especially ahead of two likely product launches in the next five years:mixed-reality headsetsandthe Apple Car.</p>\n<p><b>On the App Store risk</b></p>\n<p>I tend to agree with Dan Ives on most of the arguments that he makes about Apple and its stock. However, in my view, he does not seem worried enough about the risks associated with the App Store and the scrutiny around Apple’s highly lucrative app platform.</p>\n<p>Dan certainly recognizes the regulatory challenges. However, he sees the consequences leaning more towards fines rather than business model changes. He thinks that the risk to the 30% App Store fee is seen as contained by investors, which seems evident in lack of share price pressures as of late.</p>\n<p>I, on the other hand,believe that the business model changesare already underway. The key question in my mind is not if there will be a negative impact, but to what extent. I believe only time will answer this question with any accuracy, starting with Apple’s fiscal Q4 earnings report and fiscal Q1 guidance to be released in October.</p>\n<p><b><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> speaks</b></p>\n<p>The most bullish of Apple analysts thinks that AAPL will be valued at $3 trillion within the next 6 to 9 months. How likely do you think that this price target will materialize within this time frame?</p>\n<p><img src=\"https://static.tigerbbs.com/297d56fb43b4eb06ea483ea33f1a13cb\" tg-width=\"562\" tg-height=\"338\" referrerpolicy=\"no-referrer\"></p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: $3 Trillion Is Next, Says This Expert</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: $3 Trillion Is Next, Says This Expert\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-07 21:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/apple/news/apple-stock-3-trillion-is-next-says-this-expert><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wedbush’s Dan Ives has made a bold prediction: Apple stock will be valued at $3 trillion within six to nine months. Here is what supports his bullish thesis.\n\nWedbush analyst Dan Ives, whom the Apple ...</p>\n\n<a href=\"https://www.thestreet.com/apple/news/apple-stock-3-trillion-is-next-says-this-expert\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/news/apple-stock-3-trillion-is-next-says-this-expert","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170276114","content_text":"Wedbush’s Dan Ives has made a bold prediction: Apple stock will be valued at $3 trillion within six to nine months. Here is what supports his bullish thesis.\n\nWedbush analyst Dan Ives, whom the Apple Maven interviewed a few weeks ago, is not letting off the gas. In his opinion, Apple stock-Get Apple Inc. (AAPL) Report will be valued at $3 trillion within the next six to nine months – thus becoming the first company to ever reach this valuation milestone.\nThe Apple Maven reviews Mr. Ives’ bullish thesis and the key factors that support it. Lastly, I present one rare instance in which I disagree with the Wedbush analyst.\nIt starts with the super cycle\nDuring his interview with Bloomberg, Dan Ives explained why Apple stock should be worth $3 trillion soon, up 18% from $2.55 trillion today. At the core of the bullish case is what the analyst calls the “elongated iPhone super cycle”.\nIn my conversation with Dan, he explained that Wall Street underestimates the depth of the upgrade cycle that the iPhone 12 has merely kickstarted. Rather than one wave, he sees multiple iterations of smartphone users buying Apple’s new devices over the next few years. His quote:\n\n “If you look at it, we still have 25% of the base that has not upgraded their iPhones in the last three and a half years. 5G does not get fully embraced for the next two or three years, until the networks are built out. In China [where the 5G infrastructure is further ahead], the iPhone 12, especially the larger Pro versions, really sold extremely well.”\n\nServices and innovation\nBut not all is about iPhone sales upside. Dan also mentioned two other important factors that support his bullishness: services and technological innovations.\nOn the former, the analyst believes that this massive segment, which produces $65 billion in revenues per year and grows at a pace of 20%-plus, is worth $1.4 trillion. The 20x implied price-to-sales valuation may seem too rich, but less so if one considers the enviable 65% op margins and solid growth prospects.\nRegarding the latter, Dan points out that Apple continues to impress on the technological innovation front – something that has not been left in the rearview mirror, as some skeptics believe. I agree with this take, especially ahead of two likely product launches in the next five years:mixed-reality headsetsandthe Apple Car.\nOn the App Store risk\nI tend to agree with Dan Ives on most of the arguments that he makes about Apple and its stock. However, in my view, he does not seem worried enough about the risks associated with the App Store and the scrutiny around Apple’s highly lucrative app platform.\nDan certainly recognizes the regulatory challenges. However, he sees the consequences leaning more towards fines rather than business model changes. He thinks that the risk to the 30% App Store fee is seen as contained by investors, which seems evident in lack of share price pressures as of late.\nI, on the other hand,believe that the business model changesare already underway. The key question in my mind is not if there will be a negative impact, but to what extent. I believe only time will answer this question with any accuracy, starting with Apple’s fiscal Q4 earnings report and fiscal Q1 guidance to be released in October.\nTwitter speaks\nThe most bullish of Apple analysts thinks that AAPL will be valued at $3 trillion within the next 6 to 9 months. How likely do you think that this price target will materialize within this time frame?","news_type":1},"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":842023509,"gmtCreate":1636121445856,"gmtModify":1636121445941,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"This means long term growth!!!!","listText":"This means long term growth!!!!","text":"This means long term growth!!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842023509","repostId":"1166866310","repostType":2,"repost":{"id":"1166866310","kind":"news","pubTimestamp":1636112660,"share":"https://www.laohu8.com/m/news/1166866310?lang=&edition=full","pubTime":"2021-11-05 19:44","market":"us","language":"en","title":"Pfizer Develops Covid Pill That Cuts Hospitalizations and Deaths by 89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166866310","media":"Bloomberg","summary":"Drug reduced Covid hospitalizations by 89% in clinical trial\nPfizer shares surge 11%; Merck pill awa","content":"<ul>\n <li>Drug reduced Covid hospitalizations by 89% in clinical trial</li>\n <li>Pfizer shares surge 11%; Merck pill awaiting U.S. approval</li>\n</ul>\n<p>Pfizer Inc.&nbsp;said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%, a result that has the potential to upend how the disease caused by the coronavirus is treated and alter the course of the pandemic. The shares surged 11%.</p>\n<p>The drugmaker said in a statement on Friday that it was no longer taking new patients in a clinical trial of the treatment “due to the overwhelming efficacy” and planned to submit the findings to U.S. regulatory authorities for emergency authorization as soon as possible.</p>\n<p>The results mean there are now two promising candidates for treating Covid-19 patients early in the course of the disease. Last month,Merck &amp; Co.&nbsp;and partner Ridgeback Biotherapeutics LP submitted their experimental pill to regulators after a study showed it slashed the risk of getting seriously ill or dying&nbsp;by half&nbsp;in patients with mild-to-moderate Covid-19.</p>\n<p>Pfizer gained 11% in premarket U.S. trading, while Merck fell 6.6%. Some vaccine makers lost ground, with&nbsp;Moderna Inc&nbsp;.down 4.5% and Pfizer partner&nbsp;BioNTech&nbsp;SE slipping 4% in German trading.</p>\n<p>A pill that could be taken at home at the first sign of symptoms is a crucial tool for taming the Covid-19 crisis globally, so long as it’s widely available. A Pfizer spokesperson said submissions to other regulatory agencies will occur shortly after the U.S. filing.</p>\n<p>In Pfizer’s trial of 1,219 unvaccinated adults, five days of treatment with its drug dramatically reduced the rate of hospitalization when it was started within either three days or five days of symptom onset, the company said. The drug, Paxlovid, binds to an enzyme called a protease to stop the virus from replicating itself. Some drugs for HIV work in a similar way.</p>\n<p>Overall, just 0.8% of people who started treatment within three days of getting sick ended up in the hospital and no one died, while 7% of people who got a placebo in that window were later hospitalized or died. Similar results were found when the drug was started within five days of symptom onset. The result, which hasn’t been published in a medical journal, was highly statistically significant, Pfizer said.</p>\n<p><b>Acute Need</b></p>\n<p>Current treatment options for Covid aren’t ideal. Monoclonal antibodies from companies like&nbsp;Regeneron Pharmaceuticals Inc.&nbsp;and&nbsp;Eli Lilly &amp; Co.&nbsp;reduce hospitalizations, but the infusions are hard to manufacture and must be given in a medical office, adding to the strain on health systems.</p>\n<p>Other medications like&nbsp;Gilead Sciences Inc.’s remdesivir are used to treat much sicker people who are already in the hospital. Low-cost steroid dexamethasone, while very effective, is usually only given to gravely ill patients.</p>\n<p>The need for a pill is so acute that Merck has&nbsp;already agreed&nbsp;to allow generic drugmakers to apply for licenses to make its treatment for more than 100 low- and middle-income nations, before it has even been cleared in the U.S. The U.K.’s drug regulators became the first in the world&nbsp;to greenlight&nbsp;Merck’s drug Thursday after a swift review.</p>\n<p>Now Pfizer’s pill, which works by a different mechanism, appears to have produced even better results in high-risk patients. The trial was stopped early by independent monitors because the effect was so impressive.</p>\n<p>“We are really over the moon that we did see such high efficacy in this study. It has tremendous implications for patients globally,” said Annaliesa Anderson, chief scientific officer for Pfizer’s hospitals business unit, which includes its antiviral work.</p>\n<p>In addition to the current trial in high-risk patients, Pfizer is also testing the drug in standard-risk patients, a study that included some vaccinated people who had breakthrough infections.</p>\n<p>In a third large trial, Pfizer is exploring if the drug could be used as a prophylactic medicine for people who live with someone who has come down with Covid-19, meaning a person would take the drug to avoid contracting the virus.</p>\n<p><b>Old Molecule</b></p>\n<p>The pill was internally developed by Pfizer researchers in the U.S. and U.K. During the early pandemic shutdowns, the scientists agreed to come back to their labs in an urgent effort to develop anti-Covid pills, Anderson said. Company researchers “worked around the clock to design this molecule” in a highly-compressed timeframe, she said.</p>\n<p>They dusted off an old experimental antiviral drug that Pfizer had developed after the original SARS epidemic, a coronavirus cousin to Covid-19 that killed about 800 people starting in late 2002. The old drug needed to be administered intravenously. But by July of last year, the Pfizer researchers tweaked the original molecule and came up with a new compound that turned out to be highly potent against Covid-19 and other coronaviruses in the test tube -- and could be used as a pill.</p>\n<p>The Pfizer drug works to block a crucial enzyme that the Covid-19 virus needs to replicate. It is taken twice a day for five days and used in combination with a second medicine called ritonavir that helps the Pfizer compound stay in the bloodstream longer.</p>\n<p>Pfizer said it planned to offer the antiviral therapy through a tiered pricing approach during the pandemic. High and upper-middle income countries will pay more than lower income countries, it said. The drugmaker didn’t say exactly how much it would charge.</p>\n<p>A Pfizer spokesperson said the company currently expects to produce more than 180,000 packs of the drug by the end of this year, and anticipates making at least 50 million packs by the end of 2022, with 21 million produced in the first half of the year.</p>\n<p></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Develops Covid Pill That Cuts Hospitalizations and Deaths by 89%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Develops Covid Pill That Cuts Hospitalizations and Deaths by 89%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 19:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-to-seek-u-s-nod-for-covid-pill-after-strong-results?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Drug reduced Covid hospitalizations by 89% in clinical trial\nPfizer shares surge 11%; Merck pill awaiting U.S. approval\n\nPfizer Inc. said its Covid-19 pill reduced hospitalizations and deaths in high-...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-to-seek-u-s-nod-for-covid-pill-after-strong-results?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-to-seek-u-s-nod-for-covid-pill-after-strong-results?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166866310","content_text":"Drug reduced Covid hospitalizations by 89% in clinical trial\nPfizer shares surge 11%; Merck pill awaiting U.S. approval\n\nPfizer Inc. said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%, a result that has the potential to upend how the disease caused by the coronavirus is treated and alter the course of the pandemic. The shares surged 11%.\nThe drugmaker said in a statement on Friday that it was no longer taking new patients in a clinical trial of the treatment “due to the overwhelming efficacy” and planned to submit the findings to U.S. regulatory authorities for emergency authorization as soon as possible.\nThe results mean there are now two promising candidates for treating Covid-19 patients early in the course of the disease. Last month,Merck & Co. and partner Ridgeback Biotherapeutics LP submitted their experimental pill to regulators after a study showed it slashed the risk of getting seriously ill or dying by half in patients with mild-to-moderate Covid-19.\nPfizer gained 11% in premarket U.S. trading, while Merck fell 6.6%. Some vaccine makers lost ground, with Moderna Inc .down 4.5% and Pfizer partner BioNTech SE slipping 4% in German trading.\nA pill that could be taken at home at the first sign of symptoms is a crucial tool for taming the Covid-19 crisis globally, so long as it’s widely available. A Pfizer spokesperson said submissions to other regulatory agencies will occur shortly after the U.S. filing.\nIn Pfizer’s trial of 1,219 unvaccinated adults, five days of treatment with its drug dramatically reduced the rate of hospitalization when it was started within either three days or five days of symptom onset, the company said. The drug, Paxlovid, binds to an enzyme called a protease to stop the virus from replicating itself. Some drugs for HIV work in a similar way.\nOverall, just 0.8% of people who started treatment within three days of getting sick ended up in the hospital and no one died, while 7% of people who got a placebo in that window were later hospitalized or died. Similar results were found when the drug was started within five days of symptom onset. The result, which hasn’t been published in a medical journal, was highly statistically significant, Pfizer said.\nAcute Need\nCurrent treatment options for Covid aren’t ideal. Monoclonal antibodies from companies like Regeneron Pharmaceuticals Inc. and Eli Lilly & Co. reduce hospitalizations, but the infusions are hard to manufacture and must be given in a medical office, adding to the strain on health systems.\nOther medications like Gilead Sciences Inc.’s remdesivir are used to treat much sicker people who are already in the hospital. Low-cost steroid dexamethasone, while very effective, is usually only given to gravely ill patients.\nThe need for a pill is so acute that Merck has already agreed to allow generic drugmakers to apply for licenses to make its treatment for more than 100 low- and middle-income nations, before it has even been cleared in the U.S. The U.K.’s drug regulators became the first in the world to greenlight Merck’s drug Thursday after a swift review.\nNow Pfizer’s pill, which works by a different mechanism, appears to have produced even better results in high-risk patients. The trial was stopped early by independent monitors because the effect was so impressive.\n“We are really over the moon that we did see such high efficacy in this study. It has tremendous implications for patients globally,” said Annaliesa Anderson, chief scientific officer for Pfizer’s hospitals business unit, which includes its antiviral work.\nIn addition to the current trial in high-risk patients, Pfizer is also testing the drug in standard-risk patients, a study that included some vaccinated people who had breakthrough infections.\nIn a third large trial, Pfizer is exploring if the drug could be used as a prophylactic medicine for people who live with someone who has come down with Covid-19, meaning a person would take the drug to avoid contracting the virus.\nOld Molecule\nThe pill was internally developed by Pfizer researchers in the U.S. and U.K. During the early pandemic shutdowns, the scientists agreed to come back to their labs in an urgent effort to develop anti-Covid pills, Anderson said. Company researchers “worked around the clock to design this molecule” in a highly-compressed timeframe, she said.\nThey dusted off an old experimental antiviral drug that Pfizer had developed after the original SARS epidemic, a coronavirus cousin to Covid-19 that killed about 800 people starting in late 2002. The old drug needed to be administered intravenously. But by July of last year, the Pfizer researchers tweaked the original molecule and came up with a new compound that turned out to be highly potent against Covid-19 and other coronaviruses in the test tube -- and could be used as a pill.\nThe Pfizer drug works to block a crucial enzyme that the Covid-19 virus needs to replicate. It is taken twice a day for five days and used in combination with a second medicine called ritonavir that helps the Pfizer compound stay in the bloodstream longer.\nPfizer said it planned to offer the antiviral therapy through a tiered pricing approach during the pandemic. High and upper-middle income countries will pay more than lower income countries, it said. The drugmaker didn’t say exactly how much it would charge.\nA Pfizer spokesperson said the company currently expects to produce more than 180,000 packs of the drug by the end of this year, and anticipates making at least 50 million packs by the end of 2022, with 21 million produced in the first half of the year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848476426,"gmtCreate":1636024880577,"gmtModify":1636024880671,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"Trying market now","listText":"Trying market now","text":"Trying market now","images":[{"img":"https://static.tigerbbs.com/a2b0fe2a3113ff5d31962e4b31800c6e","width":"1242","height":"2688"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848476426","isVote":1,"tweetType":1,"viewCount":678,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":811434410,"gmtCreate":1630335533030,"gmtModify":1704958740532,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"Still good to go… target maybe can be 45","listText":"Still good to go… target maybe can be 45","text":"Still good to go… target maybe can be 45","images":[{"img":"https://static.tigerbbs.com/c7713ad8e358a483e2fff4043469478b","width":"1125","height":"3314"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/811434410","isVote":1,"tweetType":1,"viewCount":270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":819812155,"gmtCreate":1630053811577,"gmtModify":1704955236365,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"Time to go in at its lowest","listText":"Time to go in at its lowest","text":"Time to go in at its lowest","images":[{"img":"https://static.tigerbbs.com/f95d7e10867a186a145ced5d74936b71","width":"1125","height":"3395"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819812155","isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":819832406,"gmtCreate":1630053110505,"gmtModify":1704955221516,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"Interest pop up!","listText":"Interest pop up!","text":"Interest pop up!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819832406","repostId":"1105977007","repostType":4,"repost":{"id":"1105977007","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630052821,"share":"https://www.laohu8.com/m/news/1105977007?lang=&edition=full","pubTime":"2021-08-27 16:27","market":"us","language":"en","title":"SGOCO Group shares Popped 15% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1105977007","media":"Tiger Newspress","summary":"SGOCO Group shares Popped 15% in premarket trading.","content":"<p>SGOCO Group shares Popped 15% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/7c9927994703b72da979fa59d0dbe160\" tg-width=\"892\" tg-height=\"640\" referrerpolicy=\"no-referrer\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SGOCO Group shares Popped 15% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSGOCO Group shares Popped 15% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-27 16:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SGOCO Group shares Popped 15% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/7c9927994703b72da979fa59d0dbe160\" tg-width=\"892\" tg-height=\"640\" referrerpolicy=\"no-referrer\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105977007","content_text":"SGOCO Group shares Popped 15% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":56,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899736198,"gmtCreate":1628214410714,"gmtModify":1633752544292,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"AMD consolidating stock price to earnings results. If&nbsp;chip shortage prolong … prices will start to rise","listText":"AMD consolidating stock price to earnings results. If&nbsp;chip shortage prolong … prices will start to rise","text":"AMD consolidating stock price to earnings results. If chip shortage prolong … prices will start to rise","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/899736198","isVote":1,"tweetType":1,"viewCount":80,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801806323,"gmtCreate":1627494476862,"gmtModify":1631885479295,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>Good to go in… chip shortage will rebound","listText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>Good to go in… chip shortage will rebound","text":"$Intel(INTC)$Good to go in… chip shortage will rebound","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/801806323","isVote":1,"tweetType":1,"viewCount":44,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809415390,"gmtCreate":1627386711810,"gmtModify":1633765516092,"author":{"id":"4089970209759400","authorId":"4089970209759400","name":"Peter1962","avatar":"https://static.tigerbbs.com/801353fd9d0fbc9024527f43b076482d","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089970209759400","idStr":"4089970209759400"},"themes":[],"htmlText":"What is paper accou t for ?","listText":"What is paper accou t for ?","text":"What is paper accou t for ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/809415390","isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}